- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05126446
the Aorta Arch Stent Graft System Combined With the Endovascular Needle System in Situ Fenestration
January 15, 2024 updated by: Lifetech Scientific (Shenzhen) Co., Ltd.
The Aorta Arch Stent Graft System Combined With the Endovascular Needle System in Situ Fenestration Technology in the Treatment of Aortic Dissection Involving the Aortic Arch
A prospective, multi-center, single-group target value method to evaluate the safety and effectiveness of the Aorta Arch Stent Graft System combined with the Endovascular Needle System in situ fenestration technology in the treatment of aortic dissection involving the aortic arch
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
- Clinical trials using prospective, multi-center, single-group target value design;
- 120 subjects with aortic dissection requiring partial arch reconstruction will be enrolled in more than 30 centers in China, and they will meet the test enrollment requirements.
- CTA examination was performed at baseline, 30 days, 6 months, 12 months, 36 months, and 60 months after surgery to determine the pathological status and the status of postoperative aortic and branch revascularization
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Chang Shu, Professor
- Phone Number: 86 13910086222
- Email: changshu@vip.126.com
Study Locations
-
-
Hunan
-
Changsha, Hunan, China, 410011
- Recruiting
- Xiangya Second Hospital, Central South University
-
Contact:
- Chang Shu, Professor
- Phone Number: 86 13910086222
- Email: changshu@vip.126.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion criteria (to be selected if all of the following criteria are met):
- 18 years old ≤age≤80 years old, no gender limitation;
- Diagnosis of aortic dissection and reconstruction of the left subclavian artery;
The main branches and branches of the aortic arch at the lesion site have sufficient anatomical basis:
- The diameter range of the near-end anchoring zone of the main body of the fixed mechanism: 21-46mm;
- The length of the anchor zone near the principal part of the tunnel is ≥10mm;
- The length of the anchor zone of the branching vessel of the convex target is ≥15mm;
- The diameter range of the distal anchoring zone of the target branching vessel is 5-18mm.
- The patient has adequate surgical access vessels;
- Patients who understand the purpose of the study, voluntarily participate in and sign informed consent, and are willing to follow up.
Exclusion Criteria (If one of the following criteria is met, it will not be selected):
- The patient is pregnant or breastfeeding;
- The patient had a history of cardiac surgery (congenital heart disease surgery, heart valve surgery, coronary heart disease surgery, thoracic aortic surgery, etc.), which would affect the implementation of this TEVAR surgery;
- The patient has been implanted or planned to be implanted with left ventricular auxiliary pump, interventional valve and other instruments, or is planning to undergo coronary intervention surgery, and aortic dissection is expected to affect the function of such instruments or such instruments will affect the operation of aortic dissection;
- Patients with severe hematoma on the aortic wall in the proximal anchoring area of the stent;
- Marfan syndrome and other connective tissue diseases, arteritis;
- Patients with a history of allergy to contrast agents, anesthetics, antiplatelet drugs, anticoagulants, nickel peptide alloys, and polytetrafluoroethylene materials;
- Patients with a history of cerebral infarction or myocardial infarction within 3 months before surgery;
- Patients with active bleeding and coagulopathy;
- Abnormal renal function: patients with preoperative creatinine > 2.5 times the normal upper limit value;
- Abnormal liver function: patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the normal upper limit value, or patients with serum total bilirubin (STB) > 2 times the normal upper limit value;
- Patients with end-stage diseases with a life expectancy of less than one year;
- patients with poor compliance considered by the investigator;
- Patients participating in other clinical trials at the same time.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: aortic dissection involving the aortic arch
Aortic dissection involving the aortic arch was diagnosed in patients requiring revascularization of the aortic arch and its branches
|
Patients who meet all the inclusion criteria and don't meet the exclusion criteria will be implanted with device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Primary safety end point of the Aorta Arch Stent Graft System: no Major Adverse events(MAE) occurrence within 30 days after surgery
Time Frame: Within 30 days after procedure
|
MAE was defined as death related to aortic dissection, ischemic stroke, and paraplegia within 30 days after surgery
|
Within 30 days after procedure
|
Primary efficacy endpoint of the Aorta Arch Stent Graft System: treatment success at 12 months after surgery
Time Frame: 12 months after procedure
|
On the basis of successful surgery, the main and branch stents were unobstructed 12 months after surgery, with no internal leakage requiring intervention, no stent displacement (displacement ≤10mm), no new device-related rupture, and no device-induced aortic arch re-operation
|
12 months after procedure
|
Primary endpoint of the Endovascular Needle System: Immediate surgical success rate of the Endovascular Needle System
Time Frame: intraoperative
|
Intraoperative DSA, the membrane was successfully broken in situ with the membrane rupture system, and the membrane rupture system was successfully withdrawn
|
intraoperative
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Chang Shu, Professor, Xiangya Second Hospital, Central South University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 25, 2021
Primary Completion (Estimated)
March 30, 2024
Study Completion (Estimated)
March 30, 2028
Study Registration Dates
First Submitted
November 8, 2021
First Submitted That Met QC Criteria
November 8, 2021
First Posted (Actual)
November 19, 2021
Study Record Updates
Last Update Posted (Actual)
January 17, 2024
Last Update Submitted That Met QC Criteria
January 15, 2024
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LTP86-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Aortic Dissection
-
Centre Cardiologique du NordUniversita degli Studi di Genova; Henri Mondor University Hospital; Pitié-Salpêtrière...Enrolling by invitationAortic Valve Insufficiency | Aortic Diseases | Ascending Aortic Dissection | Aortic Arch | Aortic Root Dissection | Aortic Root Dilatation | Type A Aortic DissectionFrance
-
Assiut UniversityRecruitingAortic Root Aneurysm | Aortic Root DissectionEgypt
-
The University of Texas Health Science Center,...RecruitingACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy (ACUTE-B)Distal Aortic Dissection | Dissection, Aortic Acute | Acute Type B Aortic Dissection (Uncomplicated)United States
-
Petrovsky National Research Centre of SurgeryRecruitingThoracic Aortic Aneurysm | Thoracic Aortic Dissection | Cardiac Valve Disease | Aortic Aneurysm and DissectionRussian Federation
-
University of PennsylvaniaBolton MedicalEnrolling by invitationThoracic Aortic Aneurysm | Thoracic Aortic Dissection | MicroemboliUnited States
-
The University of Texas Health Science Center,...Washington University School of Medicine; University of Michigan; John Ritter...Active, not recruiting
-
Braile Biomedica Ind. Com. e Repr. Ltda.RecruitingThoracic Aortic DissectionBrazil
-
IRCCS San RaffaeleNot yet recruitingAneurysm | Aortic Arch | Dissection, Aortic
-
Hangzhou Endonom Medtech Co., Ltd.RecruitingAortic Aneurysm and DissectionChina
-
Xiaotong HouNot yet recruitingAcute Aortic DissectionChina
Clinical Trials on the Aorta Arch Stent Graft System combined with the Endovascular Needle System
-
Center for Vascular Awareness, Albany, New YorkUnknownAbdominal Aortic AneurysmUnited States
-
Cook Research IncorporatedRecruitingAortic Aneurysm, Abdominal | Juxtarenal Aortic Aneurysm | Extent IV Thoracoabdominal | Pararenal AneurysmUnited States
-
Cook Research IncorporatedActive, not recruiting
-
Medtronic CardiovascularMedtronicCompletedBlunt Thoracic Aortic InjuryUnited States, Canada
-
Medtronic CardiovascularMedtronicCompleted
-
Bolton MedicalActive, not recruitingAbdominal Aortic Aneurysm (AAA)United States
-
Cook Group IncorporatedTerminatedAorto-iliac Aneurysms | Iliac AneurysmsHong Kong, United Kingdom, Germany
-
Rijnstate HospitalMedtronicRecruitingAortic Aneurysm, AbdominalNetherlands, United States
-
Medical University of GrazActive, not recruitingHemorrhage | Polytrauma | Shock, Traumatic | Cardiac Arrest Due to TraumaAustria
-
Zhejiang Zylox Medical Device Co., Ltd.Not yet recruitingAortic DissectionChina